Skip to content

Teva Pharmaceutical Industries

US · TEVA #471 by market cap Listed 1970
39.23 +0.69 +1.79%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • Rating change
    Teva Pharmaceuticals Price Target Announced at $52.00/Share by HC Wainwright & Co.
    Dow Jones · 2026/11/2
  • Company notice
    TEVA PHARMACEUTICAL INDUSTRIES | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Phoenix Holdings Ltd.(4.83%)
    SEC · 2024/4/9
  • Company notice
    Teva Pharmaceutical Industries | 3: Initial statement of beneficial ownership of securities-Officer McAvoy David R.
    SEC · 2024/3/6
  • Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $50
    Market Newswire · 2026/11/19
  • Company notice
    Teva Pharmaceutical Industries | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Phoenix Holdings Ltd.(4.83%)
    SEC · 2024/4/9
  • HC Wainwright & Co. Reiterates Buy on Teva Pharmaceutical Indus, Maintains $54 Price Target
    Benzinga · 2026/11/17
  • Rating change
    A Quick Look at Today's Ratings for Teva Pharmaceutical Industries(TEVA.US), With a Forecast Between $54 to $57
    Market Newswire · 2026/11/13
  • Rating change
    Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $47
    Market Newswire · 2026/10/16
  • H.C. Wainwright Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $54
    Market Newswire · 2026/11/18
  • Company notice
    Teva Pharmaceutical Industries | SC 13G: Statement of acquisition of beneficial ownership by individuals-The Phoenix Holdings Ltd.(5.40%)
    SEC · 2024/2/1
  • TD Cowen Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $57
    Market Newswire · 2026/11/13
  • Company notice
    Teva Pharmaceutical Industries | 4: Statement of changes in beneficial ownership of securities-Officer McAvoy David R.
    SEC · 2024/3/6
  • Rating change
    H.C. Wainwright Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $54
    Market Newswire · 2026/11/4
  • Rating change
    A Quick Look at Today's Ratings for Teva Pharmaceutical Industries(TEVA.US), With a Forecast Between $47 to $55
    Market Newswire · 2026/11/5
  • Rating change
    Teva Pharmaceuticals Price Target Maintained With a $54.00/Share by HC Wainwright & Co.
    Dow Jones · 2026/11/17
  • Rating change
    HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54
    Benzinga · 2026/11/4
  • Rating change
    Teva Pharmaceuticals Initiated at Buy by HC Wainwright & Co.
    Dow Jones · 2026/11/2
  • Rating change
    HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus With Buy Rating, Announces Price Target of $52
    Benzinga · 2026/11/2
  • Rating change
    Scotiabank Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $47
    Market Newswire · 2026/11/4
  • Leerink Partners Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
    Market Newswire · 2026/11/20
  • Rating change
    Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/10/13
  • Rating change
    TD Cowen Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $55
    Market Newswire · 2026/10/2
  • Rating change
    Leader Capital Markets Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $49.95
    Market Newswire · 2026/10/13
  • Rating change
    BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $43
    Market Newswire · 2026/10/9
  • Teva Q3 Adj. Gross Margin 58.7%, Up 345 Bps YoY
    Benzinga · 2026/11/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:26 · For reference only, not investment advice and not tailored to your situation.

Teva Pharmaceutical Industries discussion 0 comments

Add a comment